China, AstraZeneca
AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...
The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of ...
AstraZeneca restructures its China operations following leadership scandals and sales challenges, appointing new executives ...
From accelerating drug development and clinical trials to supercharging collaboration, machine learning-enhanced healthcare ...
The Food and Drug Administration approved the drug for patients with advanced breast tumors whose cells bear a certain ...
It’s a sobering statistic: 1 in 8 women in the United States will be diagnosed with breast cancer during her lifetime.1 ...
AstraZeneca’s share price has fallen a long way from its record-breaking level last year, which indicates that I may be ...
News Medical on MSN2d
AstraZeneca's Pioneering Research in Heart Failure and ATTR-CM: An interview with Mina MakerMina Makar highlights AstraZeneca's commitment to advancing heart failure research and innovative therapies, addressing ...
Amgen’s Lumakras and AstraZeneca’s Calquence are both in line to expand their respective oncology reaches with new FDA ...
AstraZeneca PLC AZN shares inched up 0.87% to £109.38 Friday, on what proved to be an all-around great trading session for the stock market, with the FTSE 100 Index UKX rising 1.35% to 8,505.22.
Calquence in combination with bendamustine and rituximab has been approved in the US for the treatment of adult patients ...
AstraZeneca’s Fasenra, an IL-5-targeting monoclonal antibody already approved for asthma, represents a promising contender ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback